SEP 15 2006 8

PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0551-0031
U.S. Patent and Trademank Officex U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information untess it displays a valid CMB control number.

Express Mail Label No. EV204058987US

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

<u>ss Mail Label No. E</u>	V204058987US
Application Number	10/520768
Filing Date	01/10/2005
First Named Inventor	Jean F. Lacrampe
Group Art Unit	1624
Examiner Name	V. Balasubramanian
Attorney Docket Number	JAB 1701USWO

		U.S. Patent Document					
Examiner Initials	Cite No.1	Number	Kind Cods ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages o relevant figures appear	
W		4568649 t		Immunex Corporation	02-04-1986		
W)		6174889	B1	Glaxo Wellcome Inc.	01-16-2001		
<u> </u>							
		····					
			FORE	IGN PATENT DOCUMENTS		I	

Examiner Cite Initials No.1	•	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	Ī
	Cite No.1	Office ³	Number Ki	ndCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	Ţ₫
m		JP	09-255681	A	Taisho Pharmaceutical Co. Ltd.& English Abstract & Translation	09-30-1997		x
m		JP	07-041479	B2	Taisho Pharmaceutical Co. Ltd. & English Abstract	02-10-1995		
M		WO 02/20525 A2		WO 02/20525 A2 Institute of Molecular And Cell 03-14-2002 Biology		03-14-2002		
7								
								_

Examiner Signature	V. Balasulan	MIAM	Date Considered	10/1	186	

*EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must pracede the serial number of the patent document. S Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, s Applicant is to place a check mark here II English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Tredemark Officer, Washington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Petents, P.O. Box 1450, Alexandria, VA 22313-1450

PTC/S8/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Express Mail Label No. EV204058987US

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

ADECOS PALE DOSCE NO.	2120103051.00
Application Number	10/520768
Filing Date	01/10/2005
First Named Inventor	Jean F. Lacrampe
Group Art Unit	1624
Examiner Name	V. Balasubramanian
Attorney Docket Number	JAB 1701USWO

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's nitials*	Cite No.1	(book, magazine, journal, serial, sympostum, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
VB		ABRAHAM et al., "Cellular Effects of Olomoucine, An Inhibitor of Cyclin-Dependent Kinases.", <u>Biol., Cell.</u> , 1995, pages 105-120, Vol. 83.	
M		DELIA, Thomas, "Fused Pyrimidines, Part Four, Miscellaneous Fused Pyrimidines: Chapter VI-Pyrimidotriazines.", Heteropyclic Compounds, John Wiley & Sons, Inc., Interscience Publications, pages 261-304.	<u>.</u>
M		GENNARO et al. <u>Reminuton's Pharmacoutical Sciences</u> , 19 th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmacoutical preparations and their Manufacture,	
W		GREENE et al., "Protective Groups in Organic Synthesis", 2 rd edition, Wiley Interscience, 1991.	
M		KAUR et al., "Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L88-8275.", <u>Journal of the National Cancer Institute</u> , Nov. 18, 1992, pages 1738-1740, Vol. 84, No.22.	
W		MEUER, Laurent, "Chemical Inhibitors of Cyclin-Dependent Kinases.", <u>Progress in Cell Cycle Research</u> , 1995, pages 351-363, Vol.1.	
W		NAGAMATSU et al., "Sytheses of 3-Substituted 1-Methyl-6-Phenylpyrimido[5,4-e]-1,2,4-triazine-5,7(1H,8H)-diones (6- Phenyl Analogs of Toxoflavin) and Their 4-Oxides, and Evaluation of Antimicrobial Activity of Toxoflavins and Their Analogs.", Chem Pharm Bull., 1993, pages 362-368, Vol 41, No. 2.	
W		NAGAMATSU et al., "Facile And General Syntheses of 1-Alkyltoxoflavins and 8-Alkyltervenutin Derivatives of Biological Significance By The Regiospecific Alkylation of Reumycin (1-Demethyltoxoflavin, 8-Demethylfervenutin) Derivatives.", Heterocycles, 1997, pages 643-650, Vol. 45, No. 4.	
M		NAGAMATSU et at., "General Syntheses of 1-Alkyftoxoftevin and 8-Alkyftervenulin Derivatives of Biological Significance By The Regioselective Alytation of Reumychn Derivatives And The Rates of Transalkytation From 1-Alkyftoxoftavins Into Nucleophiles.", J. Chem. Soc. Perkin Trans. 1, 2001, pages 130-137.	
M	1	"Protective Groups in Organic Chemistry", edited by J W F McOmle, 1973, Plenum Press.	
W		SEDLACEK et al., "Flavopirido! (L88 8275; NSC 649890), A New Kinase Inhibitor For Turnor Therapy.", International Journal of Oncology, 1996, pages 1143-1168, Vol. 9.	
W		SMIRNOVA et al., "Purines, Pyrimidines, And Condensed Systems Based on Them. 9."Concerning The Synthesis of 1- R-Pyrazolo(3,4-d)Pyrimidine-4,6-Diones.", 1992, pages 181-185, Plenum Publishing Corporation- <u>Translated from</u> Khimiya Geterotsiklicheskikh Soedinenii, Feb. 1992, pages 219-224, No. 2.	
W		STREITWEISER, A., "Introduction to Omanic Chemistry.", Second Ed., Macmillan Publishing Inc., pages 1104-1105.	
W		VESELY et al., "Inhibition of Cyclin-Dependent Kinases By Purine Analogues.", <u>Eur. J. Blochem.</u> , 1994, pages 771-786. Vol. 224.	
W		YONEDA et al.,"A Convenient Synthesis of Toxoflavins And Toxoflavin-N-Oxides.", <u>Tetrahedron Letters</u> , 1971, pages 851-854, Vol. 13, Pergamon Press, Great Britain.	
W		YONEDA et at., "Transformation of Toxoflavins Into Fervenulin Via 1-Demethyltoxoflavins.", Tetrahedron Letters, 1973, pages 1577-1580, No. 17, Pergamon Press, Great Britain:	
.W		YONEDA et al., "Synthesis and Properties of 6-Benzyl Analogs of Toxoflavin.", Journal of Heterocyclic Chemistry, 1974, pages 83-85, Vol. 11, No.1.	
W		YONEDA et al., "A New Method For The Transformation of Toxoflavins to Fervenulins.", Journal of Heterocyclic Chemistry, 1974, pages 271-273, Vo. 11, No. 2.	
M		YONEDA et al., "A New Synthetic Method of Toxoflavin Derivatives.", Synthesis, March 1975, pages 177-179, Vol. 3.	
W		YONEDA et al., "A Convenient Synthesis of Toxoffavins, Toxoffavin 4-oxides and 1-Demethyltoxoffavins.", Chem. Pharm, Bull., 1975, pages 2001-2009, Vol. 23, No. 9.	•
w		YONEDA et al., "New Syntheses of Fervenulin (1,3-Dimethyl-7-azakmazine) and Analogs.". <u>Butletin of The Chemical Society of Japan</u> , 1975, pages 2884-2887, Vol. 48, No. 10.	
M,		YONEDA et al., "A New Synthesis of Pyrimido[4,5-e]-as-triazine 4-Oxides by Nitrosative Cyclization of Aldehyde Uracil- 6-ylhydrazones in the Presence of Diethyl Azodformate.", Journal of the Chemical Society, 1976, pages 713-715, Vol. 7.	· .
M	·	YONEDA et al., *6-Azapurines (Imidazo[4,5-e]-as-triazines).*, <u>Journal of The Chemical Society, Chemical Communications</u> , 1976, pages 658-659, Vol.16.	
M		YONEDA et al., "Syntheses of Isoallozazines, Toxoflavins, and Ferrenulins By Oxidative Cyclization of the Michael-type Adducts from Substituted 6-Aminouracits and Azo-Compounds.", <u>Journal of The Chemical Society</u> , Perkin Transactions I, 1976, pages 2398-2402, Vol. 22.	

Examiner Signature V. Ballisunawawamam	Date Considered	10/1/06
--	-----------------	---------

[&]quot;EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

SEP 1 5 2006

Express Mail Label No. EV204058987US

SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number 10/520768
Filing Date 01/10/2005
First Named Inventor Jean F. Lacrampe
Group Art Unit 1624
Examiner Name V. Balasubramanian
Attorney Docket Number JAB 1701USWO

L		raye i oi i	ATE		CHINAENTO						
	7	U.S. F	-		CUMENTS						
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	F	U.S. Patent Document Kind Code ⁴ Number (il known)				Pages, Columns, Lines, where relevant passages or relevant figures appear			
	No.	<u> </u>	-+	Teamber (a)			1	Too to a significant			
	ـــــ		\dashv					<u> </u>	ļ		
								l		·	
9.1						•	•				
											
			十					 -			
	-					·					
			-					ļ			
											
							<u> </u>			,	
	L		L								
									·		
		FOREIG	N PAT	ENT (DOCUMEN	ιτs					
			Fore	oreign Patent Document Pages,					Columns, Lines, elevant passages		
Examiner	Cite	Name of Patentee or Applicant of Cited Document					or relevant figures Te		τ•		
tnitials	No.'	No.¹			Office ³ Number ⁴ KindCode ⁵				appear		
<u> </u>			<u> </u>			\bot					
						·			•		
•			Ī								
						\top			-		
						\top			_		
			⇈			+					
	 		┼			╫					
	<u> </u>	OTHER PRIOR ART - N	LON DA	TENT	MEDATI	OE DO	TIME	TE		<u> </u>	
	\Box	Include name of the author (in C	APITO	OL LE	ITERS), ti	tle of t	he arti	de (when	appropriate),		
Examiner 's Initials*	Cite No.1	title of the Item (book, magazine volume-issue number(s	e, jourr	nal, se	rial, sympo	osium,	catalo	g, etc.), d	late, pege(s),	T²	
VB		International Search Report, Internat International Search Report May 14, 20	donal /	Applica	tion Numbe	# PCT	/EP03/	50292, Da	ate of Mailing of		
		· · · · · · · · · · · · · · · · · · ·									
	+		_		-		-				
	ļ							·			
<u></u>		<u> </u>	-								
Examiner	1/.	Balasulvamanan		351	Date		-	0/1/	16		
Signature	V · /	" I'M JUNDAN MYZUNOWAM-			Considere	od L	ι	$\sigma H I$	0.6		